Effects of denosumab on bone histomorpho
β
Ian R Reid; Paul D Miller; Jacques P Brown; David L Kendler; Astrid Fahrleitner-
π
Article
π
2010
π
American Society for Bone and Mineral Research
π
English
β 115 KB
π 2 views
## Abstract Denosumab, a human monoclonal antibody against RANKL, reversibly inhibits osteoclastβmediated bone resorption and has been developed for use in osteoporosis. Its effects on bone histomorphometry have not been described previously. Iliac crest bone biopsies were collected at 24 and/or 36